University of Kentucky

UKnowledge
Epidemiology and Environmental Health Faculty
Publications

Epidemiology and Environmental Health

3-2018

Demographic, Presentation, and Treatment Factors and Racial
Disparities in Ovarian Cancer Hospitalization Outcomes
Tomi F. Akinyemiju
University of Kentucky, tomiakin@uky.edu

Gurudatta Naik
University of Alabama at Birmingham

Kemi Ogunsina
University of Alabama at Birmingham

Daniel T. Dibaba
University of Kentucky, daniel.dibaba@uky.edu

Neomi Vin-Raviv
University of Northern Colorado

Follow this and additional works at: https://uknowledge.uky.edu/epidemiology_facpub
Part of the Epidemiology Commons, Oncology Commons, and the Rehabilitation and Therapy
Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Akinyemiju, Tomi F.; Naik, Gurudatta; Ogunsina, Kemi; Dibaba, Daniel T.; and Vin-Raviv, Neomi,
"Demographic, Presentation, and Treatment Factors and Racial Disparities in Ovarian Cancer
Hospitalization Outcomes" (2018). Epidemiology and Environmental Health Faculty Publications. 64.
https://uknowledge.uky.edu/epidemiology_facpub/64

This Article is brought to you for free and open access by the Epidemiology and Environmental Health at
UKnowledge. It has been accepted for inclusion in Epidemiology and Environmental Health Faculty Publications by
an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Demographic, Presentation, and Treatment Factors and Racial Disparities in
Ovarian Cancer Hospitalization Outcomes
Digital Object Identifier (DOI)
https://doi.org/10.1007/s10552-018-1010-7

Notes/Citation Information
Published in Cancer Causes & Control, v. 29, no. 3, p. 333-342.
The copyright holder has granted the permission for posting the article here.
This is a post-peer-review, pre-copyedit version of an article published in Cancer Causes & Control. The
final authenticated version is available online at: https://doi.org/10.1007/s10552-018-1010-7

This article is available at UKnowledge: https://uknowledge.uky.edu/epidemiology_facpub/64

HHS Public Access
Author manuscript
Author Manuscript

Cancer Causes Control. Author manuscript; available in PMC 2019 March 01.
Published in final edited form as:
Cancer Causes Control. 2018 March ; 29(3): 333–342. doi:10.1007/s10552-018-1010-7.

Demographic, Presentation and Treatment Factors and Racial
Disparities in Ovarian Cancer Hospitalization Outcomes
Tomi F Akinyemiju1,2,3,*, Gurudatta Naik1,2, Kemi Ogunsina1, Daniel T. Dibaba3, and Neomi
Vin-Raviv4,5

Author Manuscript

1University

of Alabama at Birmingham, Department of Epidemiology, Birmingham, AL

2University

of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, AL

3University

of Kentucky, Department of Epidemiology, Lexington, KY

4University

of Northern Colorado Cancer Rehabilitation Institute, Greeley, CO

5Colorado

State University, School of Social Work, College of Health and Human Sciences, Fort
Collins, CO

Abstract
Background—This study examines whether racial disparities in hospitalization outcomes persist
between African-American and White women with ovarian cancer after matching on
demographic, presentation and treatment factors.
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Methods—Using data from the Nationwide Inpatient Sample database, 5,164 African-American
ovarian cancer patients were sequentially matched with White patients on demographic (e.g. age,
income), presentation (e.g. stage, comorbidities) and treatment (e.g. surgery, radiation) factors.
Racial differences in-hospital length of stay, post-operative complications and in-hospital mortality
were evaluated using conditional logistic regression models.
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Results—White ovarian cancer patients had relatively higher odds of post-operative
complications when matched on demographics (OR=1.35, 95% CI: 1.05, 1.74), and presentation
(OR=1.28, 95% CI: 1.00, 1.65) but not when additionally matched on treatment (OR=1.03, 95%
CI: 0.78, 1.35). African-American patients had longer in-hospital length of stay (6.96 ± 7.21 days)
compared with White patients when matched on demographics (6.37 ± 7.07 days), presentation
(6.48 ± 7.16 days) and treatment (6.53±7.59 days). Compared with African-American patients,
White patients experienced lower odds of in-hospital mortality when matched on demographics
(OR = 0.78, 95% CI: 0.66, 0.92), but this disparity was no longer significant when additionally
matched on presentation (OR=0.88, 95% CI: 0.75, 1.04) and treatment (OR=0.95, 95% CI: 0.81,
1.12).
Conclusion—Racial disparities in ovarian cancer hospitalization outcomes persisted after
adjusting for demographic and presentation factors, however these differences were eliminated
after additionally accounting for treatment factors. More studies are needed to determine the
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factors driving racial differences in ovarian cancer treatment in otherwise similar patient
populations.

Introduction

Author Manuscript

Ovarian cancer remains one of the most lethal gynecologic cancers in the United States, with
an estimated 22,280 new cases diagnosed and 14,240 deaths in 2016[1]. Although AfricanAmerican patients have lower incidence of ovarian cancer compared with White patients,
they experience significantly higher mortality rates [2, 3], a trend that has worsened in the
past several decades [4]. Several factors have been reported to contribute to racial disparities
in ovarian cancer outcomes, including sociodemographic factors, access to healthcare,
comorbidities and biological differences [5–10]. African-American patients are also more
likely to be diagnosed at later stages [11, 12], present with more aggressive tumors [13] and
have a poorer response to treatment [4]. Once diagnosed, African-American patients are less
likely to receive standard care or evidence-based treatment, which includes primary
cytoreductive surgery and chemotherapy in line with the National Comprehensive Cancer
Network (NCCN) guidelines [14–16]. These differences contribute to poorer survival
outcomes in African-American patients [17–20]. Lack of access to guideline-adherent care
is likely a major contributing factor to ovarian cancer disparities, as studies examining
patients in equal access settings have observed similar health outcomes [21–23].

Author Manuscript

Few studies to date have systematically and simultaneously evaluated multiple contributors
to racial disparities in ovarian cancer outcomes. Here, we examined if racial disparities
persist among hospitalized ovarian cancer patients after sequentially matching on
demographics, presentation and treatment variables [24]. Moreover, we examined whether
racial differences were larger among older (65 years+) compared with younger patients, and
pre-compared with post-Affordable Care Act implementation.

Methods and Materials
Data Source

Author Manuscript

We analyzed data from the Healthcare Cost Utilization Project National Inpatient Sample
(HCUP-NIS) for the years 2007-2011. The NIS is a national database of inpatient discharge
data maintained by the Agency for Healthcare Research and Quality. The NIS database
includes records on about 39 million all-payer inpatient visits across 10,000 hospitals in the
US [26]. The database includes detailed information on patient admissions, including
diagnoses and procedures (International Classification of Diseases, Ninth Revision, Clinical
Modification [ICD-9-CM] codes), as well as patient socio-demographic information and
hospital characteristics. More details on HCUP-NIS database can be obtained at http://
www.hcupus.ahrq.gov/nisoverview.jsp [26]. The study population comprised of ovarian
cancer (ICD-9 code: 183.0) patients who were African-American and ages 40 years or older
matched with White patients on demographics, presentation and treatment characteristics.
Demographic Characteristics—Patient demographic variables used in matching
included age, residential region, health insurance, and median income of household in a
residential area. Age was recorded in years; residential region was derived from number of
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people staying in counties and categorized as - 1) Large Metropolitan counties (≥ 1 million
population), 2) Small Metropolitan counties (population between 50,000 and 999,999), 3)
Micropolitan counties (population between 10,000 and 49,999) and 4) Non-metropolitan and
non-micropolitan counties. Median income in a household for a residential area was
categorized as – 1) Lowest Quartile (≤ $25,000 per year), 2) Second Quartile (between
$25,001 and $34,999 per year), 3) Third Quartile (between $35,000 and $44,999 per year)
and 4) Highest Quartile (≥ $45,000).

Author Manuscript

Presentation Characteristics—These include data on stage at diagnosis and
comorbidity index at admission. The NIS does not include staging information on individual
cancer diagnosis, therefore a proxy ovarian cancer stage variable was defined and cases
characterized as metastatic, non-metastatic and in-situ (not including carcinoma in-situ
ICD-9 codes). A Modified Deyo Comorbidity Index [27] was created to estimate individual
burden of multiple comorbidities such as cerebrovascular disease, congestive heart failure,
diabetes mellitus, dementia, myocardial infarction, rheumatic diseases, peptic ulcer disease,
liver disease, renal disease and HIV/AIDs. Comorbid conditions were identified using ICD-9
codes, and each assigned a value of one (1) for each condition if present. The scores were
summed up for each individual to obtain a comorbidity index score.

Author Manuscript

Treatment Characteristics—Ovarian cancer is predominantly treated by surgery, while
radiation therapy and chemotherapy are given to prevent or mitigate spread of disease from
primary site [28]. Using ICD-9 codes, we identified all patients who received surgery (open
or laparoscopic), radiation and/or chemotherapy. Although hysterectomies are also
performed for non-cancer etiologies, we only included patients that had removal of ovaries
along with hysterectomies to avoid including treatment outcomes for non-cancer related
surgeries.

Author Manuscript

Study Outcomes—Four inpatient outcomes were evaluated – 1) Length Of Stay (LOS),
defined as the total number of days hospitalized, with same day discharge being counted as
one day; 2) Post-operative complications after surgical treatment for ovarian cancer,
including systemic inflammatory response syndrome/septic shock, puncture wounds,
disruption of operative wound, traumatic injury during operation, infections, foreign body
left inside the body, non-healing wounds and other unspecified complications identified by
appropriate ICD-9 codes; 3) In-hospital mortality, defined as deaths during hospitalization
due to any reason; and 4) patient discharge disposition-a patient-centered quality measure,
comparing individuals recovering at home with those with more protracted recovery periods
in a nursing home or other facility (28). Codes for Discharge disposition were obtained from
NIS dataset [26] and included: 1) Routine discharge (discharge to the patient’s home with no
health care assistance); 2) discharge to a skilled nursing facility; 3) expired and; 4) Other
classified as discharged due to any other short-term hospital, intermediate care facility, any
other facility or discharged against medical advice.
Statistical analyses—To evaluate whether racial differences in study outcomes persisted
after adjusting for demographic, presentation and treatment variables, we conducted a series
of multivariate matched analyses similar to approaches used in recent studies [25, 29, 30].
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African-American ovarian cancer patients that met our inclusion criteria were included in
the study, and first, compared with White ovarian cancer patients in crude analysis. Next, a
propensity score was generated using logistic regression analysis with race as the outcome
(African-American vs. White) and each set of matching variables as predictors (e.g. for
demographic matching, predictors were age, region, health insurance and income).
Propensity scores for each matched analysis (i.e. demographics, presentation and treatment)
are balanced between groups using greedy matching by selecting one White patient
representing the best match based on propensity score with an African-American patient,
without replacement. This approach is typically used in observational studies to mimic
randomized studies where randomization enables unbiased estimation of treatment effects.
By evaluating differences in hospitalization outcomes comparing matched African-American
and White patients, the possibility of bias due to differences in the matched variables among
African-Americans and Whites is minimized. To evaluate between-group balance of
matched variables after matching, we conducted Wilcoxon signed-rank test on matched
continuous variables and McNemar’s test on matched categorical variables. The signed rank
P-value > 0.05 indicates no significant differences in the means of matched continuous
variables between the two groups, and the McNemar’s test k-statistic value > 0.50 was
considered adequate for matching categorical variables.

Author Manuscript
Author Manuscript

Three consecutive models were generated to compare outcomes among African-American
and White patients matched on demographics only, demographics and presentation, and
demographics, presentation and treatment respectively. Conditional logistic regression
analysis was used to account for the matched study design and evaluate racial differences in
in-hospital mortality, t-tests were used to evaluate differences in length of stay and the
Pooled or Satterthwaite P-values were reported depending on equality of variances, while
linear regression models were used to adjust for study covariates. Odds ratios (for postoperative complications and in-hospital mortality) and ß coefficient estimates (for hospital
length of stay) and 95% confidence intervals were presented. Multinomial logistic regression
was used to evaluate disparities in discharge disposition, using ‘discharge to home’ as the
reference category. All analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC).
Ethical Consideration
This study was considered exempt by the Institutional Review Board at the University of
Alabama at Birmingham, as the HCUP-NIS database is a publicly available and deidentified data source.

Results
Author Manuscript

There were 49,761 women ages 40 years or older with a primary diagnosis of ovarian cancer
represented in the dataset. African-American patients comprised about 10% (n=5,164) of
these patients while the rest were White (90%, n=44,597). About 47% of patients presented
with metastatic cancer, and 23% received surgery for treatment of ovarian cancer, while 11%
of patients received chemotherapy. Table 1 shows the descriptive characteristics of 5,164
White patients matched with 5,164 African-American patients. The matched variables were
statistically balanced between African-American and White patients (Appendix 1), except
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number of comorbidities at presentation, which remained significantly higher on average
among African-Americans compared with Whites (P=0.03). After matching on
demographics, 48% of African-American patients presented with metastatic cancer
compared with 46% of Whites (P= 0.02). However, there were no racial differences in stage
when additionally matched on presentation and treatment. About 17% of African-American
patients received surgery compared with 24% of White patients (P= <0.0001); this
difference persisted even when additionally matched on presentation (17% vs 25%, P= <
0.0001), but disappeared when additionally matched on treatment (17% vs. 18%, P= 0.835).
Further, African-American patients had higher mean number of comorbidities compared
with Whites (Mean ± SD: 0.48 ± 0.74 vs. 0.38 ± 0.67), however this difference disappeared
when additionally matched on presentation characteristics. About 17% of African-American
patients had Medicaid insurance coverage compared with 8% of White patients when
matched on demographics, 8% when further matched on presentation and 8% when further
matched on treatment.

Author Manuscript

Table 2 describes racial differences in hospitalization outcomes among matched AfricanAmerican and White patients. Compared with African-American patients, White patients
experienced higher odds of post-operative complications when matched on demographic
factors (OR=1.35, 95% CI=1.05, 1.74), but this difference became non-significant when
additionally matched on presentation (OR=1.28, 95% CI: 1.00, 1.65) and treatment
(OR=1.03, 0.78, 1.35). White patients also experienced significantly shorter hospital length
of stay compared with African-American patients when matched on demographics (β=
−0.60, P=<0.001), presentation (β= −0.46, P=<0.001) and treatment (β= −0.43, P=0.003).
Compared with African-American patients, White patients experienced significantly lower
odds of in-hospital mortality when matched on demographics (OR=0.78, 95% CI: 0.66,
0.92), however no racial difference remained when additionally matched on presentation
(OR=0.88, 95% CI: 0.75, 1.04), and treatment (OR=0.95, 95% CI: 0.81, 1.12). White
patients were less likely to be discharged to other intermediate facilities or discharged
against advice compared with African-American ovarian cancer patients after matching on
demographics, presentation and treatment variables (OR= 0.89, 95% CI: 0.80, 0.98), but
there was no statistically significant difference in being discharged to skilled nursing homes
(OR=1.01, 95% CI: 0.92, 1.11).

Author Manuscript

Table 3 presents the results of age-stratified analyses. Among patients less than 65 years at
hospitalization, there were no significant differences in hospitalization outcomes between
African-American patients and White patients matched on demographic, presentation and
treatment characteristics. However, among patients ages 65 years and older, average LOS
was significantly lower among White patients even after adjusting for demographics,
presentation and treatment (β= −0.63, P=0.003). In addition, White patients experienced
significantly lower odds of in-hospital mortality when matched on demographics and
presentation (OR= 0.77, 95% CI: 0.62, 0.96), but not after additionally matching on
treatment (OR = 0.81, 95% CI: 0.65, 1.00). We conducted stratified analysis comparing
patients admitted pre-2010 (Affordable Care Act implementation start year) and post-2010
(Table 4). There were no statistically significant differences in post-operative complications
and in-hospital mortality comparing White and African-American patients in models
sequentially matched on demographics, presentation and treatment pre-2010. However,
Cancer Causes Control. Author manuscript; available in PMC 2019 March 01.
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post-2010, White patients had statistically significant higher odds of post-operative
complications compared with African-American patients in models sequentially matched on
demographics (OR=1.69, 95%CI: 1.12, 2.56), presentation (OR=1.62, 95%CI: 1.08, 2.44),
but not after matching on treatment (OR=1.39, 95%CI: 0.91, 2.13). White patients also
experienced lower odds of in-hospital mortality compared with African-American patients
after matching on demographics (OR=0.73, 95% CI: 0.57, 0.92), presentation (OR=0.79,
95% CI: 0.63, 0.99), and treatment (OR=0.76, 95% CI: 0.60, 0.96).

Discussion

Author Manuscript

This study examined whether racial disparities in hospitalization outcomes persist after
adjusting for differences in demographics, presentation and treatment among patients with
ovarian cancer. We accounted for known prognostic factors that influence ovarian cancer
survival and may contribute to disparities between African-American and White patients,
specifically age, income, insurance, residential area, stage at diagnosis, comorbidities and
receipt of treatment. After matching on demographic variables, African-Americans
experienced longer hospital length of stay, and had higher odds of post-surgical
complications and in-hospital mortality compared with Whites. However, after additionally
adjusting for presentation and treatment variables, racial differences in mortality and postsurgical complication were no longer significant, although length of stay remained
significantly shorter among White patients.

Author Manuscript

Several factors may contribute to persistent disparities in hospitalization outcomes observed
in the current study. First, we observed that African-American patients had a significantly
higher comorbidity index even after matching on multiple conditions as part of the Deyo
Comorbidity Index, and comorbidities are highly correlated with poorer health outcomes
following surgical or medical treatment of ovarian cancer patients [31, 32]. It is possible that
other conditions not included in the measure of comorbidities may be differentially
distributed by race, contributing to inadequate matching among African-American and
White patients. The higher burden of comorbidities and higher proportion of metastatic
disease among African-American patients may explain why length of stay remained
significantly higher in African-American patients compared with White patients. However,
future studies will be needed to determine why White patients were more likely to receive
surgery compared with African-American patients even though all patients were admitted,
and theoretically had already accessed care. Primary data will be needed to determine
whether these differences are due to due to patient preferences, financial factors such as
insurance status and/or negative perceptions of the benefit of surgery [33, 34].

Author Manuscript

Insurance differences persisted between African-American and White patients even after
matching, and this may have been an important factor in the disparities observed in
hospitalization outcomes. After matching on demographics, about 17% of African-American
patients were on Medicaid, while 30% had private insurance, compared with 8% of White
patients on Medicaid, and 39% with private insurance. Insurance status has been shown to
influence health outcomes for other cancer types [35], and this may be due to treatment
delays, quality of treatment, as well as access to preventive care prior to diagnosis that may
influence the underlying health status of patients during admission [36–41]. Interestingly, we
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observed that the racial disparities in length of stay and in-hospital mortality were only
observed among older patients (ages 65 years and older) but not younger patients. Although
we expected racial differences to be larger in the younger age groups due to larger variations
in insurance coverage (since adults are eligible for Medicare insurance after age 65), our
findings may be due to age differences in the course of disease, such that older patients may
have had disease for a long time with deteriorating effects on their health and poorer
response to treatment. Overall, older patients in this study (48%) tended to present with
metastatic cancer compared with younger patients (45%), and had a greater burden of
comorbidities (mean=0.46, SD=0.73) compared with younger patients (mean=0.29,
SD=0.59). However, younger African-Americans patients were more likely to present with
metastatic ovarian cancer (50%) than older African-American patients (47%) and older
White patients (48%). Further studies are required to fully explore this finding, however it is
possible that there were no racial disparities observed among younger patients after
matching because the matched variables better captured the range of demographic,
presentation and treatment differences by race in this age-group.

Author Manuscript

Post-discharge care after an inpatient hospital admission is a major challenge for patients
with cancer, and studies demonstrate that discharge to skilled nursing facilities are
associated with worse clinical outcomes including postoperative complications, more
frequent readmissions, and increased mortality [42–44]. Our results showed that AfricanAmerican patients were less likely to receive routine discharge to home following a
hospitalization compared with White patients, and recent studies have indicated that
African-American patients have higher odds of hospital readmissions following a discharge
for a surgical procedure compared with Whites [45]. There may be racial differences in
social support and coping mechanisms leading to the higher likelihood of non-routine
discharge for African-American patients, however the Nationwide Inpatient Sample does not
include information on post-discharge settings. Future studies examining post-discharge
health outcomes by race, including re-admissions and quality of life will help shed light on
post-treatment factors important for ovarian cancer survival.
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We also observed that racial disparities in hospitalization outcomes were most pronounced
after, but not before, the implementation of the Affordable Care Act in 2010. It is possible
that while health insurance may have improved one aspect of access to care post-2010, i.e.
financial burden and out of pocket expenses, there are likely racial differences in other
dimensions such as availability and accessibility of high volume providers, potentially
explaining racial differences observed post ACA. Recent studies have shown that high
volume hospitals have better ovarian cancer survival rates compared with low volume
hospitals [46], and that treatment at NCI Designated Comprehensive Cancer Centers is
associated with better adherence to treatment related guidelines, and lower ovarian cancer
related mortality compared with non-NCI designated centers. Future studies examining
multiple components of access to care simultaneously will be needed to better highlight
barriers to the receipt of high quality ovarian cancer care among African-Americans and
Whites.
There are several limitations relevant to this analysis. First, cancer stage information was
based on ICD-9 codes, and as such there is a possibility of misclassification of disease stage
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in matched analysis. Length of stay represents a measure of overall health during
hospitalization, and may have been influenced by receipt of other procedures or treatment
not necessarily restricted to the primary admission for ovarian cancer alone. Information on
individual level socioeconomic factors such as education and income were not available in
the dataset to better adjust for potential confounding by these factors, however we utilized
data on individual level insurance status and area socioeconomic status. The analysis was
restricted to African-American and White patients who had been admitted to the hospital
and therefore theoretically had already accessed healthcare. Therefore, results may not be
generalizable to the overall US population with varying levels of healthcare access. The
strength of this analysis include the large sample size which enabled analysis of a relatively
rare cancer outcome, and examination of race- and age-differences in outcomes. The use of
clinical diagnostic codes to identify ovarian cancer cases and administrative claims data to
identify receipt of treatment also enhanced the quality of the analysis by further minimizing
misclassification bias. Data from the Nationwide Inpatient Sample also represents inpatient
stays and discharges from US hospitals in 46 states in 2011, covering 97% of the US
population, and significantly enhancing the generalizability of study results.

Conclusion

Author Manuscript

After sequentially matching on demographics, presentation, and treatment characteristics,
African American ovarian cancer patients did not have higher in-hospital mortality, although
they tended to have longer average lengths of stay in the hospital. Racial differences in
discharge disposition also persisted. These may be due to residual racial differences in
clinical factors such as burden of comorbidities and metastatic disease, and/or racial
differences in utilization of quality ovarian cancer treatment due to differences in access to
quality healthcare. Future studies with a combination of primary patient reported data,
detailed treatment information, as well as hospital and provider characteristics will be
needed to further elucidate the causes of disparate ovarian cancer outcomes.

Appendix 1
Matching balance test result using signed rank test for continuous variables and McNemar’s
test for categorical variables

Author Manuscript

Demographic matched

Presentation matched

Treatment matched

Age

0.5021 (P-value)

0.0874 (P-value)

0.7041 (P-value)

Income

0.9249 (K statistic)

0.7914 (K statistic)

0.7318 (K statistic)

Region

0.9063 (K statistic)

0.7116 (K statistic)

0.6526 (K statistic)

Comorbidities

0.0315 (P-value)

0.0039 (P-value)

Stage

0.6075 (K statistic)

0.5696 (K statistic)

Surgery

0.4822 (K statistic)

K statistic is from McNemar’s test.
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Whites represent White patients diagnosed with ovarian cancer in the dataset. Patients stratified based on year of admission.
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